Compare Stocks: ORMP, AVTX, MDXG, and DSGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$11.98 -0.3%	$17.41	$11.72 ▼ $24.27	$642.70M	0.68	1.14 million shs	208,966 shs
DSGN Design Therapeutics	$9.86 +0.8%	$13.73	$5.28 ▼ $17.25	$613.97M	1.68	596,126 shs	107,544 shs
MDXG MiMedx Group	$4.69 -0.1%	$4.53	$3.03 ▼ $7.97	$682.89M	1.18	1.26 million shs	89,142 shs
ORMP Oramed Pharmaceuticals	$4.18 +0.3%	$4.66	$2.09 ▼ $5.47	$173.93M	1.29	222,305 shs	11,641 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-9.29%	-11.63%	-25.50%	-35.26%	-12.14%
DSGN Design Therapeutics	-10.36%	-18.30%	-33.15%	-27.66%	+50.69%
MDXG MiMedx Group	-2.90%	+1.52%	+2.63%	+9.84%	-27.96%
ORMP Oramed Pharmaceuticals	-2.34%	-4.79%	-10.52%	+2.71%	+73.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$11.98 -0.3%	$17.41	$11.72 ▼ $24.27	$642.70M	0.68	1.14 million shs	208,966 shs
DSGN Design Therapeutics	$9.86 +0.8%	$13.73	$5.28 ▼ $17.25	$613.97M	1.68	596,126 shs	107,544 shs
MDXG MiMedx Group	$4.69 -0.1%	$4.53	$3.03 ▼ $7.97	$682.89M	1.18	1.26 million shs	89,142 shs
ORMP Oramed Pharmaceuticals	$4.18 +0.3%	$4.66	$2.09 ▼ $5.47	$173.93M	1.29	222,305 shs	11,641 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-9.29%	-11.63%	-25.50%	-35.26%	-12.14%
DSGN Design Therapeutics	-10.36%	-18.30%	-33.15%	-27.66%	+50.69%
MDXG MiMedx Group	-2.90%	+1.52%	+2.63%	+9.84%	-27.96%
ORMP Oramed Pharmaceuticals	-2.34%	-4.79%	-10.52%	+2.71%	+73.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	276.49% Upside
DSGN Design Therapeutics	2.89	Moderate Buy	$17.86	81.20% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	82.95% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ORMP, AVTX, MDXG, and DSGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$26.00
10/2/2026	DSGN Design Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$26.00
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/15/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C+)
8/27/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
8/27/2026	MDXG MiMedx Group	Craig Hallum Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$6.00 ➝ $8.00
8/17/2026	MDXG MiMedx Group	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$8.00
8/17/2026	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$8.00
8/13/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$60K	10,707.23	N/A	N/A	$4.49 per share	2.67
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
MDXG MiMedx Group	$418.63M	1.63	$0.54 per share	8.72	$1.73 per share	2.71
ORMP Oramed Pharmaceuticals	$2M	86.96	$0.09 per share	47.07	$5.02 per share	0.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	117.15	27.56	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	1.01	N/A	N/A	N/A	-5.17%	-4.54%	11/12/2026 (Estimated)

Latest ORMP, AVTX, MDXG, and DSGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AVTX Avalo Therapeutics	-$0.5946	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	DSGN Design Therapeutics	-$0.38	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	MDXG MiMedx Group	$0.0003	N/A	N/A	N/A	$68.56 million	N/A
8/10/2026	Q2 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.09	-$0.52	$1.84	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	6.00%	N/A	6.07%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
DSGN Design Therapeutics	N/A	18.86	18.86
MDXG MiMedx Group	0.07	5.33	4.79
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
DSGN Design Therapeutics	56.64%
MDXG MiMedx Group	79.15%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
DSGN Design Therapeutics	17.10%
MDXG MiMedx Group	2.50%
ORMP Oramed Pharmaceuticals	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
MDXG MiMedx Group	808	145.76 million	142.12 million	Optionable
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable

ORMP, AVTX, MDXG, and DSGN Headlines

Recent News About These Companies

Financial Contrast: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)

October 8, 2026 | americanbankingnews.com

Oramed Pharmaceuticals stock trades at USD 4.49 after insider sale

October 4, 2026 | ad-hoc-news.deA

Oramed Pharmaceuticals (NASDAQ:ORMP) COO Joshua Hexter Sells 30,000 Shares of Stock

October 3, 2026 | americanbankingnews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Avraham Gabay Sells 20,000 Shares of Stock

October 3, 2026 | insidertrades.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $90,200.00 in Stock

October 2, 2026 | marketbeat.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $135,300.00 in Stock

October 2, 2026 | marketbeat.com

Oramed officer proposes USD 140,100 sale of Oramed Pharmaceuticals stock

October 2, 2026 | ad-hoc-news.deA

Oramed Pharmaceuticals consensus price target increased 12.00% to $7.14

September 15, 2026 | msn.com

Oramed: Q2 Earnings Snapshot

August 11, 2026 | chron.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

July 3, 2026 | insidertrades.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

June 25, 2026 | prnewswire.com

ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community

June 18, 2026 | msn.com

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 17, 2026 | prnewswire.com

ORMP: Strategically acquiring interests in medtech & technology companies

June 8, 2026 | msn.com

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

May 22, 2026 | seekingalpha.com

Oramed Pharmaceuticals Inc.

May 18, 2026 | marketwatch.com

Oramed Pharmaceuticals Delays Quarterly SEC Filing

May 15, 2026 | tipranks.com

Oramed Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:ORMP

May 15, 2026 | benzinga.com

Oramed Pharmaceuticals Incorporated

April 15, 2026 | edition.cnn.com

Oramed Pharmaceuticals (ORMP) price target increased by 92.31% to 6.38

March 27, 2026 | msn.com

Oramed: Q4 Earnings Snapshot

March 26, 2026 | stamfordadvocate.comS

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, AVTX, MDXG, and DSGN Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$11.98 -0.03 (-0.26%)

As of 10:57 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Design Therapeutics NASDAQ:DSGN

$9.86 +0.08 (+0.77%)

As of 10:57 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

MiMedx Group NASDAQ:MDXG

$4.68 -0.01 (-0.11%)

As of 10:56 AM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Oramed Pharmaceuticals NASDAQ:ORMP

$4.18 +0.01 (+0.26%)

As of 10:55 AM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, AVTX, MDXG, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, AVTX, MDXG, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, AVTX, MDXG, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, AVTX, MDXG, and DSGN Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Design Therapeutics NASDAQ:DSGN

MiMedx Group NASDAQ:MDXG

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORMP, AVTX, MDXG, and DSGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORMP, AVTX, MDXG, and DSGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORMP, AVTX, MDXG, and DSGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP, AVTX, MDXG, and DSGN Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Design Therapeutics NASDAQ:DSGN

MiMedx Group NASDAQ:MDXG

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools